Author's response to reviews

Title: Poor sleep quality is associated with increased arterial stiffness in Japanese patients with type 2 diabetes mellitus

Authors:

Yusuke Osonoi (Yu.osonoi@gmail.com)
Tomoya Mita (tom-m@juntendo.ac.jp)
Takeshi Osonoi (t-osonoi@kensei-kai.com)
Miyoko Saito (t-saitou@kensei-kai.com)
Atsuko Tamasawa (a-tamasawa@kensei-kai.com)
Shiho Nakayama (micshiho@yahoo.co.jp)
Yuki Someya (yksomeya@juntendo.ac.jp)
Hidenori Ishida (h-ishida@kensei-kai.com)
Akio Kanazawa (akana@juntendo.ac.jp)
Masahiko Gosho (robin_gosho@yahoo.co.jp)
Yoshio Fujitani (fujitani@juntendo.ac.jp)
Hirotaka Watada (hwatada@juntendo.ac.jp)

Version: 4
Date: 16 May 2015

Author's response to reviews: see over
Dear Editor

Ref. MS5736308291595728
Thank you for your e-mail letter dated May 9, 2015, regarding our manuscript by Osonoi Y et al entitled: “Poor sleep quality is associated with increased atrial stiffness in Japanese patients with type 2 diabetes mellitus”

We are pleased to know that our manuscript is potentially of interest.

According to valuable comments and suggestions from you and the reviewers, we have revised our manuscripts. Please find the attached revised versions of our manuscript. All changes made in the text have been highlighted in red color to notice them with ease.

Response to Reviewer 1 comments:

We thank the reviewer for evaluating our manuscript.

Response to Reviewer 2 comments:

We thank the reviewer for evaluating our manuscript. The following text describes our response to the valuable comments made by the reviewer. All changes made in the text are highlighted in underline and red color.

1. Please revise the column headings in Table 2 and Table 3 from "est" "Est1etc" to be text that makes more sense to the reader. A suggestion would be "unadjusted" instead of "Est" then "Model 1" instead of Est1, Model 2 etc.

Thank you for your comment. We revised the column headings.
P24 Table 2
P25 Table 3

2. Please revise the title of Table 3 to include "results of regression models" to improve clarity
re which results are presented here

Thank you for your comment. We included “results of regression models”

P25 Table 3

3. Please report HbA1c in SI units of mmol/mol (dual reporting would be acceptable if preferred)

Thank you for your comment. We reported the HbA1c in SI units.

P25 Table 3

4. Some minor changes to English language are suggested as follows:
   - abstract line 61, delete "group" after "sleep quality"
   - background line 70, suggest replace "problems" with "factors"

Thank you for your comments. We corrected them.

P3 line 61: brachial-ankle pulse wave velocity (baPWV) tended to be higher in patients with poor sleep quality group.

P4 line 70: The onset and development of type 2 diabetes mellitus (T2DM) is associated with numerous lifestyle problems factors.

Again, we would like to thank you and the reviewers for valuable comments and suggestions. We hope that our manuscript is now suitable for publication for Journal of Diabetes Investigation. We would appreciate for your kind arrangements and considerations.

All authors have read and agree to the publication of the manuscript. The manuscript has not been submitted elsewhere. We wrote our manuscript based on editorial policies of Endocrine Disorders.

The authors declare conflict of interest as below.
T.M. received research funds from MSD, Takeda and Eli Lilly. T.O. has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Ono Pharmaceutical Co., Novo Nordisk Pharma, Kissei Pharma, Mitsubishi Tanabe Pharma, Novartis Pharmaceuticals, Sanwakagaku Kenkyusho, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD,
Dainippon Sumitomo Pharm., Kowa Co. and research funds from Novo Nordisk Pharma, Dainippon Sumitomo Pharma. A.K. has received lecture fees from Kissei Pharma, Sanofi-Aventis and Takeda Pharmaceutical Co. M.G. has received lecture fee from Novartis Pharmaceuticals. Y.F. has received lecture fees from Novartis Pharmaceuticals and Eli Lilly, research funds from Novartis Pharmaceuticals, MSD and Takeda Pharmaceutical Co. H.W. has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Ono Pharmaceutical Co., Novo Nordisk Pharma, Novartis Pharmaceuticals, Eli Lilly, Sanwakagaku Kenkyusho, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Dainippon Sumitomo Pharm., Kowa Co. and research funds from Boehringer Ingelheim, Pfizer, Mochida Pharmaceutical Co., Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Sanwakagaku Kenkyusho, Terumo Corp. Eli Lilly, Mitsubishi Tanabe Pharma, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Shionogi, Pharma, Dainippon Sumitomo Pharma, Kissei Pharma, and Astrazeneca.

Sincerely,

Tomoya Mita MD, PhD, tom-m@juntendo.ac.jp.
Juntendo University, School of Medicine
Department of Medicine, Metabolism and Endocrinology

Response to Reviewer 1 comments:
We thank the reviewer for evaluating our manuscript.

Response to Reviewer 2 comments:
We thank the reviewer for evaluating our manuscript. The following text describes our response to the valuable comments made by the reviewer. All changes made in the text are highlighted in underline and red color.

1. Please revise the column headings in Table 2 and Table 3 from "est" "Est1etc" to be text that makes more sense to the reader. A suggestion would be "unadjusted" instead of "Est" then "Model 1" instead of Est1, Model 2 etc.

Thank you for your comment. We revised the column headings.

2. Please revise the title of Table 3 to include "results of regression models" to improve clarity re which results are presented here

Thank you for your comment. We included “results of regression models”

3. Please report HbA1c in SI units of mmol/mol (dual reporting would be acceptable if preferred)

Thank you for your comment. We reported the HbA1c in SI units.

4. Some minor changes to English language are suggested as follows:
   - abstract line 61, delete "group" after "sleep quality"
   - background line 70, suggest replace "problems" with "factors"

Thank you for your comments. We corrected them.